Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A randomized, open-label study of the effect of a long-term calcineurin inhibitor-free maintenance regimen with CellCept and sirolimus on preservation of renal function and prevention of acute rejection in recipients of an orthotropic liver transplant.

Next Previous
Trial Profile

A randomized, open-label study of the effect of a long-term calcineurin inhibitor-free maintenance regimen with CellCept and sirolimus on preservation of renal function and prevention of acute rejection in recipients of an orthotropic liver transplant.

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 03 Nov 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Mycophenolate mofetil (Primary) ; Sirolimus (Primary) ; Ciclosporin; Tacrolimus
  • Indications Liver transplant rejection
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms STN; STN
  • Sponsors Roche

Most Recent Events

  • 03 Jun 2009 Results were reported at the American Transplant Congress -- 9th Joint Congress of the American Society of Transplant Surgeons (ASTS) and the American Society of Transplantation (AST).
  • 18 Aug 2008 Status change from in progress to completed according to the Roche protocol registry.
  • 04 Jun 2008 Interim results presented at the American Transplant Congress (ATC) 2008.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top